Literature DB >> 24530089

Capture recapture estimation of the prevalence of mild intellectual disability and substance use disorder.

Joanneke E L VanDerNagel1, Marion Kiewik2, Marloes G Postel3, Marike van Dijk4, Robert Didden5, Jan K Buitelaar6, Cor A J de Jong7.   

Abstract

Persons with mild to borderline intellectual disability (MID) have been identified as a group at risk for substance use disorder (SUD). However, prevalence estimates of co-occurring SUD and MID rely largely on single source studies performed in selected samples. To obtain more reliable population estimates of SUD and MID, this study combines data from an Intellectual Disability Facility (IDF), and an Addiction Treatment Centre (ATC) in a semi-rural area in the Netherlands. Capture-recapture analysis was used to estimate the hidden population (i.e., the population not identified in the original samples). Further analyses were performed for age and gender stratified data. Staff members reported on 88 patients with SUD and MID in the IDF (4.0% of the IDF sample) and 114 in the ATC (5.2% of the ATC sample), with 12 patients in both groups. Only strata for males over 30 years provided reliable population estimates. Based on 97 patients in these strata, the hidden population was estimated at 215. Hence the estimated total population of males over 30 years old with MID and SUD was 312 (95% CI 143-481), approximately 0.16% (0.05-0.25%) of the total population of this age and gender group. This illustrates that while patients with co-occurring SUD and MID often receive professional help from only one service provider, single source data underestimate its prevalence, and thus underestimate treatment and service needs. Therefore, population prevalence estimations of co-occurring SUD and MID should be based on combined multiple source data.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Capture recapture method; Intellectual disability; Prevalence estimation; Substance use disorder

Mesh:

Year:  2014        PMID: 24530089     DOI: 10.1016/j.ridd.2014.01.018

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  6 in total

1.  Estimating the Number of People Who Inject Drugs in A Rural County in Appalachia.

Authors:  Sean T Allen; Allison O'Rourke; Rebecca Hamilton White; Kristin E Schneider; Michael Kilkenny; Susan G Sherman
Journal:  Am J Public Health       Date:  2019-01-24       Impact factor: 9.308

2.  A national profile of substance use disorder among Medicaid enrollees on the autism spectrum or with intellectual disability.

Authors:  Anne M Roux; Sha Tao; Steven Marcus; Viktor Lushin; Lindsay L Shea
Journal:  Disabil Health J       Date:  2022-03-07       Impact factor: 4.615

3.  Evaluating a selective prevention program for substance use and comorbid behavioral problems in adolescents with mild to borderline intellectual disabilities: Study protocol of a randomized controlled trial.

Authors:  Esmée P Schijven; Rutger C M E Engels; Marloes Kleinjan; Evelien A P Poelen
Journal:  BMC Psychiatry       Date:  2015-07-22       Impact factor: 3.630

4.  Substance-related and addictive disorders among adults with intellectual and developmental disabilities (IDD): an Ontario population cohort study.

Authors:  Elizabeth Lin; Robert Balogh; Caitlin McGarry; Avra Selick; Kristin Dobranowski; Andrew S Wilton; Yona Lunsky
Journal:  BMJ Open       Date:  2016-09-02       Impact factor: 2.692

5.  Factors Associated with Likelihood of Initiating Others into Injection Drug Use Among People Who Inject Drugs in West Virginia.

Authors:  Sean T Allen; Kristin E Schneider; Alyona Mazhnaya; Rebecca Hamilton White; Allison O'Rourke; Alex H Kral; Ricky N Bluthenthal; Michael E Kilkenny; Susan G Sherman
Journal:  AIDS Behav       Date:  2021-06-02

6.  Prevalence and Characteristics of Borderline Intellectual Functioning in a Cohort of Patients With Polysubstance Use Disorder.

Authors:  Jens Hetland; Kirsten J Braatveit; Egon Hagen; Astri J Lundervold; Aleksander H Erga
Journal:  Front Psychiatry       Date:  2021-07-14       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.